EU Pharmacovigilance legislation implementation likely to be staggered
This article was originally published in Scrip
As the European Medicines Agency struggles to finance implementing the far reaching pharmacovigilance legislation, it looks as if the new requirements will be introduced in phases beyond the original July 2012 implementation deadline, confirmed Peter Arlett, head of pharmacovigilance and risk management at the European Medicines Agency.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.